Synthesis and profile of SCH351591, a novel PDE4 inhibitor

  • Bioorg Med Chem Lett. 2002 Jun 17;12(12):1621-3. doi: 10.1016/s0960-894x(02)00225-1.
Motasim Billah  1 ,  Nicola Cooper ,  Francis Cuss ,  Richard J Davenport ,  Hazel J Dyke ,  Robert Egan ,  Ashit Ganguly ,  Lewis Gowers ,  Duncan R Hannah ,  Alan F Haughan ,  Hannah J Kendall ,  Christopher Lowe ,  Michael Minnicozzi ,  John G Montana ,  Robert Naylor ,  Janet Oxford ,  Joanna C Peake ,  John J Piwinski ,  Karen A Runcie ,  Verity Sabin ,  Andrew Sharpe ,  Neng-Yang Shih ,  Julie B H Warneck
Affiliations
  • 1. Schering-Plough Corporation, Galloping Hill Road, Kenilworth, NJ 07033-0530, USA.
PMID: 12039576 DOI: 10.1016/s0960-894x(02)00225-1
Abstract

The syntheses and pharmacological profiles of some 2-trifluoromethyl-8-methoxyquinoline-5-carboxamides are described. SCH351591 is a potent selective inhibitor of phosphodiesterase type 4 (PDE4).